Professor Alan Cass
BA, MBBS, Grad Dip Clinical Epidemiology, FRACP, PhD|
Professor and Co-Director
Phone: +61 2 9993 4553 |
(Update details) |
Publications |
|
|
Peer Reviewed/Refereed Journal Articles Ninomiya T, Perkovic V, Verdon C, Barzi F, Cass A, Gallagher M, Jardine M, Anderson C, Chalmers J, Craig J, Huxley R. Proteinuria and stroke: A meta-analysis of cohort studies. American Journal of Kidney Diseases. 2009; 53(3):417-425 Howard K, Salkeld G, White S, McDonald S, Chadban S, Craig JC, Cass A. The cost-effectiveness of increasing kidney transplantation and home-based dialysis. Nephrology. 2009;14(1):123-132 White SL, Perkovic V, Cass A, Chang CL, Poulter NR, Spector T, Haysom L, Craig JC, Salmi IA, Chadban SJ, Huxley RR. Is Low Birth Weight an Antecedent of CKD in Later Life? A Systematic Review of Observational Studies. American Journal of Kidney Diseases. 2009;54(2):248-261, Perkovic V, Verdon C, Ninomiya R, Barzi F, Cass A, Patel A, jardine M, Gallagher M, Turnbull F, Chalmers J, Craig J, Huxley R. The Relationship between proteinuria and coronary risk: A systematic review and meta-analysis. PLoS Medicine 2008;5(10)e207. White, S.L., McGeechan, K., Jones, M., Cass, A., Chadban, S.J., Polkinghorne, K.R., Perkovic, V., Roderick, P.J. Socioeconomic Disadvantage and Kidney Disease in the United States, Australia and Thailand. American Journal of Public Health 2008;98(7):1306-1313. |
|
Projects |
|
Community preferences for organ donation and allocation in AustraliaK Howard, A/Prof S Jan, Prof A Cass, Dr. J Rose, Dr. S Chadban, Prof R. Allen. Community preferences for organ donation and allocation in Australia. ARC Discovery Grant. $240,000 2009 - 2011 ACTIVE Dialysis: A Clinical Trial of InvesiVE DialysisCass A, Perkovic V, Howard K, McDagar JW, Hawley C, Kerr PG. *through the George Institute* NHMRC Project Grant #571045. $1,248,175 People with kidney disease requiring dialysis have substantially reduced life expectancy and quality of life. Better treatments are therefore urgently required. ACTIVE Dialysis is a clinical trial that aims to assess whether increased duration of dialysis improves these critical outcomes for affected patients. A formal cost-effectiveness analysis will also be performed. The results of this study have the potential to improve the health and longevity of many thousands of Australians. 2009-2012 Erythropoiesis Stimulating Agents Trialists\' CollaborationCass A, Perkovic V, Huxley R, Baigent D, Levin A. *through the George Institute* NHMRC Project Grant # 571047. $104,750 Erythropoiesis Stimulating Agents are used to correct the anaemia associated with kidney disease, and cost Australia around $100m in 2004. The optimal target haemoglobin remains the subject of intense debate despite several large trials in the area. This project will use pooled data from these trials to provide a definitive analysis of the overall harms and benefits associated with different targets for the first time and will guide the use of these expensive drugs to maximise patient benefit. 2009-2011 Making a difference – Interventions for Aboriginal health improvementEades S, Bailey S, Banks E, Butow P, Cass A, D’Este C, Jan S, Kaldor J, Kippax S, Leask J, McIntyre P, Nutbeam D, Redman S, Sanson-Fisher R, Thompson S. The program will build skills in the development and evaluation of intervention programs to improve Aboriginal health outcomes. It will focus on the health of Aboriginal people living in urban and regional centres and examine (i) child and adolescent health and (ii) chronic disease. The program is led by two indigenous people and will build capacity in six indigenous early career researchers and a further three from non-indigenous backgrounds in (i) the development of research partnerships with Aboriginal communities; (ii) the identification of potentially effective interventions (iii) the investigation of the impact of health interventions and (iv) the integration of research with policy. NHMRC Capacity Building Grant: ($2.317m 2007- 11) |
|